CBD for Insomnia: Clinical Research, Efficacy Evidence, and Sleep Science

Executive Summary

Cannabidiol (CBD) has emerged as one of the most studied non-intoxicating cannabinoids for sleep disorders, with clinical research accelerating since 2018 following hemp legalization under the U.S. Agriculture Improvement Act. While preclinical evidence suggests CBD may influence sleep architecture through interactions with serotonin receptors, GABA pathways, and the endocannabinoid system, human clinical trials have produced mixed results. The largest randomized controlled trial to date, launched by Australian pharmaceutical company Avecho Biotechnology in 2025, enrolled 1,200 participants with chronic insomnia and reported preliminary findings in July 2026 showing statistically significant improvements in sleep latency and total sleep time compared to placebo. This trial utilized a proprietary lipid-based delivery system designed to enhance CBD bioavailability, a critical factor given the compound's poor oral absorption profile. The research landscape remains fragmented, with dosing protocols ranging from 25 mg to 600 mg daily across studies, and regulatory pathways diverging sharply between jurisdictions that classify CBD as a dietary supplement, prescription medicine, or controlled substance.

The commercial stakes are substantial. The global CBD market reached $4.9 billion in 2025, with sleep products representing the fastest-growing segment at 28% compound annual growth rate, according to data from Grand View Research. However, the U.S. Food and Drug Administration has issued more than 50 warning letters since 2019 to companies making unapproved therapeutic claims about CBD sleep products, creating a regulatory gray zone that distinguishes between marketing wellness benefits and treating diagnosed insomnia. Meanwhile, pharmaceutical-grade CBD formulations face the lengthy drug approval process, with only one CBD medication—Epidiolex for epilepsy—currently approved by FDA. The Avecho trial results, if they lead to regulatory approval in Australia through the Therapeutic Goods Administration, could establish the first government-sanctioned CBD insomnia medication and reshape the competitive landscape for both pharmaceutical companies and the broader hemp-derived CBD industry.

Why This Matters

Insomnia affects approximately 30% of adults globally, representing a $100 billion annual market for sleep aids, while CBD products occupy an increasingly contested space between dietary supplements and pharmaceutical interventions.

The clinical validation of CBD for insomnia carries implications across multiple stakeholder groups. For patients, an estimated 70 million Americans experience chronic sleep disorders, with many seeking alternatives to traditional hypnotics like benzodiazepines and Z-drugs (zolpidem, eszopiclone) due to concerns about dependence, next-day sedation, and cognitive impairment. Survey data from the American Sleep Association indicates that 11% of adults with insomnia reported using CBD products in 2025, despite limited clinical evidence supporting efficacy.

For the pharmaceutical industry, establishing CBD as an evidence-based insomnia treatment would create a new drug category distinct from existing mechanisms of action. Current FDA-approved sleep medications primarily target GABA-A receptors or orexin receptors, while CBD's proposed mechanisms involve serotonin 5-HT1A receptor agonism, adenosine reuptake inhibition, and modulation of cortisol secretion. Companies including Jazz Pharmaceuticals, Takeda, and Idorsia have invested heavily in novel insomnia drugs, with the market projected to reach $6.8 billion by 2028 according to GlobalData forecasts.

Regulatory agencies face the challenge of reconciling widespread consumer CBD use with the absence of rigorous safety and efficacy data for most products. The FDA's position since 2019 has been that CBD cannot be legally marketed as a dietary supplement because it was investigated as a drug before being marketed in food, creating enforcement tensions with the hemp industry. The Federal Trade Commission has pursued deceptive advertising cases against CBD companies making sleep claims without substantiation. State regulators in California, New York, and Ohio have implemented varying testing and labeling requirements for hemp-derived CBD products.

For the hemp and cannabis industries, pharmaceutical validation of CBD could either legitimize the broader market or create a two-tier system where prescription formulations gain credibility while over-the-counter products face increased scrutiny. The U.S. Hemp Roundtable has advocated for FDA to establish a regulatory framework for CBD dietary supplements, arguing that the current policy vacuum harms both consumers and compliant businesses.

Background and History

Scientific interest in cannabinoids and sleep dates to the 1970s, but CBD-specific insomnia research emerged primarily after 2014 when changing legal frameworks enabled clinical investigation of isolated cannabinoids.

Early Cannabinoid Sleep Research (1973-2000)

The first controlled studies of cannabis and sleep were conducted in the early 1970s at Stanford University and the University of Chicago, examining whole-plant cannabis containing both THC and CBD. A 1973 study published in Psychopharmacologia by Pivik and colleagues found that 20 mg of THC reduced REM sleep and increased slow-wave sleep in healthy volunteers, but these studies did not isolate CBD's effects. Throughout the 1980s and 1990s, sleep research focused predominantly on THC and synthetic cannabinoids, with CBD receiving minimal attention due to its non-intoxicating properties and limited commercial interest.

Endocannabinoid System Discovery (1988-1995)

The identification of cannabinoid receptors CB1 and CB2 between 1988 and 1993, followed by the discovery of endogenous cannabinoids anandamide and 2-arachidonoylglycerol (2-AG), established the biological framework for understanding how phytocannabinoids might influence physiological processes including sleep-wake regulation. Research by Raphael Mechoulam at Hebrew University and others demonstrated that the endocannabinoid system plays a role in circadian rhythm regulation and sleep homeostasis, though CBD's weak affinity for CB1 and CB2 receptors suggested it acted through alternative mechanisms.

CBD Isolation and Early Pharmacology (2000-2013)

Between 2000 and 2013, preclinical research began elucidating CBD's pharmacology beyond cannabinoid receptors. Studies identified CBD as an agonist at serotonin 5-HT1A receptors, an inverse agonist at GPR55, and a modulator of adenosine signaling through inhibition of adenosine reuptake. A 2004 study in the Journal of Psychopharmacology by Murillo-Rodríguez and colleagues demonstrated that CBD increased wakefulness in rats during the light period, suggesting alerting effects rather than sedation. This finding complicated the hypothesis that CBD would improve sleep, though researchers noted that effects might differ in pathological states versus healthy subjects.

U.S. Hemp Legalization and Market Emergence (2014-2018)

The 2014 Farm Bill authorized state hemp pilot programs, enabling limited cultivation of cannabis plants containing less than 0.3% THC. This created the first legal pathway for domestic CBD production, though the compound remained in a regulatory gray area. The CBD market exploded following the 2018 Agriculture Improvement Act, which removed hemp from Schedule I of the Controlled Substances Act. By 2019, CBD products were widely available in retail stores, online, and through direct-to-consumer channels, with sleep formulations representing one of the top three product categories alongside pain and anxiety.

Epidiolex Approval and Regulatory Precedent (2018)

In June 2018, FDA approved Epidiolex (purified CBD oral solution) for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, marking the first cannabis-derived drug to receive federal approval. The approval was based on four randomized controlled trials involving 714 patients, establishing safety data at doses up to 20 mg/kg/day. GW Pharmaceuticals (acquired by Jazz Pharmaceuticals in 2021 for $7.2 billion) conducted the trials, which provided the most comprehensive human safety dataset for pharmaceutical-grade CBD. However, FDA explicitly stated that Epidiolex approval did not mean CBD was safe for other uses or in other formulations, and reiterated that CBD products could not be marketed as dietary supplements.

Early Clinical Sleep Trials (2018-2022)

The first published randomized controlled trial specifically examining CBD for insomnia appeared in 2019, conducted by researchers at the University of São Paulo. The small study (n=27) found that 300 mg of CBD did not significantly improve sleep quality compared to placebo in healthy volunteers. A 2019 retrospective case series published in The Permanente Journal by Scott Shannon and colleagues examined 72 adults with anxiety and sleep complaints who received CBD; 66.7% reported improved sleep scores in the first month, though the open-label design limited conclusions about efficacy.

A 2021 study published in Medicines by Suraev and colleagues examined 1,521 patients prescribed medicinal cannabis in Australia, finding that those using CBD-dominant products reported significant improvements in sleep quality, though most formulations contained some THC. The lack of placebo control and reliance on self-reported outcomes limited the strength of evidence.

Bioavailability Challenges and Delivery Innovation (2020-2025)

A critical limitation identified across early trials was CBD's poor oral bioavailability, estimated at 6-13% for standard oil formulations due to extensive first-pass metabolism and low aqueous solubility. This prompted development of enhanced delivery systems including nanoemulsions, liposomal formulations, and self-emulsifying drug delivery systems (SEDDS). Avecho Biotechnology's TPM (Tocopheryl Phosphate Mixture) technology, licensed from the University of Western Australia, claimed to increase CBD bioavailability by 300-500% compared to standard oils, enabling lower doses to achieve therapeutic blood levels.

Avecho Trial Launch and Design (2025)

In March 2025, Avecho Biotechnology announced enrollment in a Phase III randomized, double-blind, placebo-controlled trial examining TPM-formulated CBD for chronic insomnia. The trial, conducted across 15 sites in Australia, enrolled 1,200 participants aged 18-65 with diagnosed insomnia disorder meeting DSM-5 criteria. Participants received either 50 mg CBD in TPM formulation or placebo nightly for 12 weeks, with primary endpoints of sleep latency measured by polysomnography and patient-reported sleep quality using the Insomnia Severity Index. The trial design included objective sleep measurement through both polysomnography at baseline and week 12, and daily actigraphy monitoring throughout the study period.

Preliminary Results Announcement (July 2026)

On July 13, 2026, Avecho released preliminary topline results indicating that CBD treatment resulted in a mean reduction in sleep latency of 23 minutes compared to 11 minutes for placebo (p<0.001), and an increase in total sleep time of 47 minutes versus 18 minutes for placebo (p<0.001). The company announced plans to submit a New Drug Application to the Australian Therapeutic Goods Administration in the fourth quarter of 2026, with potential market authorization in 2027. If approved, the product would become the first prescription CBD medication specifically indicated for insomnia in any jurisdiction.

Key Players

Avecho Biotechnology

Avecho Biotechnology, an Australian pharmaceutical company founded in 2003 and publicly traded on the Australian Securities Exchange (ASX: AVE), developed the TPM drug delivery platform originally for vitamin E delivery. The company pivoted to cannabinoid formulations in 2018, licensing technology from the University of Western Australia. Avecho's strategy focuses on pharmaceutical-grade CBD products requiring regulatory approval rather than consumer wellness products, positioning the company to potentially secure market exclusivity through patent protection and data exclusivity provisions. The company reported expenditures of AUD $18.3 million on the insomnia trial through fiscal year 2025.

U.S. Food and Drug Administration

FDA has maintained since 2019 that CBD cannot be marketed in dietary supplements or conventional foods because it was investigated as a drug (Epidiolex) before being marketed in food. The agency has stated it is working on a regulatory pathway for CBD products but has not issued proposed rules as of July 2026. FDA's position creates a disconnect between federal policy and widespread state-level CBD sales, with the agency prioritizing enforcement against products making disease claims or containing dangerous contaminants. The agency's Center for Drug Evaluation and Research evaluates CBD pharmaceutical applications, while the Center for Food Safety and Applied Nutrition handles potential dietary supplement frameworks.

Australian Therapeutic Goods Administration

The TGA regulates therapeutic goods in Australia through a risk-based framework. CBD was down-scheduled from Schedule 4 (prescription-only) to Schedule 3 (pharmacist-only) for low-dose products in 2021, but insomnia indications would require full prescription drug approval through the TGA's New Drug Application process. The TGA's approval would likely influence regulatory decisions in other jurisdictions including Canada, the United Kingdom, and European Union member states that often reference Australian drug approvals in their own review processes.

Jazz Pharmaceuticals

Jazz Pharmaceuticals, which acquired Epidiolex manufacturer GW Pharmaceuticals in 2021, holds the only FDA-approved CBD drug and extensive clinical safety data. The company has not publicly announced insomnia trials for Epidiolex, focusing instead on expanding approved epilepsy indications and investigating other GW pipeline compounds. Jazz reported Epidiolex sales of $687 million in 2025, demonstrating commercial viability for pharmaceutical CBD despite high pricing ($32,500 annual wholesale cost) compared to hemp-derived CBD products.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of hemp industry stakeholders, has advocated for FDA to establish clear regulatory pathways for CBD dietary supplements and foods. The organization argues that the current policy vacuum harms consumers by preventing quality standards and forcing products into unregulated markets. The group has supported legislation including the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, introduced in Congress in 2025 but not yet passed, which would direct FDA to issue regulations within 180 days.

National Institutes of Health

The National Center for Complementary and Integrative Health, part of NIH, has funded several CBD research projects including sleep studies. A 2024 NCCIH-funded study at Johns Hopkins University examined CBD's effects on sleep in individuals with chronic pain, finding no significant improvement in sleep quality at 400 mg daily doses. NIH's National Institute on Drug Abuse has also funded CBD research, primarily focusing on potential therapeutic applications for substance use disorders and anxiety, with sleep often measured as a secondary outcome.

Legal and Regulatory Framework

CBD occupies a complex legal position where hemp-derived products are federally legal under the 2018 Farm Bill but cannot be marketed as dietary supplements or with therapeutic claims under FDA authority, while state laws create a patchwork of additional requirements.

Federal Controlled Substances Act

The Agriculture Improvement Act of 2018 (Public Law 115-334) amended the Controlled Substances Act to exclude hemp, defined as cannabis containing not more than 0.3% delta-9 THC on a dry weight basis, from Schedule I. This removed hemp-derived CBD from DEA jurisdiction for cultivation and interstate commerce. However, 21 U.S.C. § 812 still classifies cannabis containing above 0.3% THC as Schedule I, and CBD derived from such cannabis remains a controlled substance requiring DEA registration for research or pharmaceutical development.

Federal Food, Drug, and Cosmetic Act

Under 21 U.S.C. § 321(ff)(3)(B), a substance that was investigated as a drug before being marketed as a dietary supplement or food cannot be sold as a supplement. FDA has interpreted this provision to prohibit CBD in dietary supplements because Epidiolex clinical trials began before CBD was widely marketed in foods. The agency has issued warning letters to companies making structure-function claims about CBD products, and has stated that only through the drug approval process or a specific regulatory framework (not yet created) can CBD be legally marketed for therapeutic purposes.

FDA Enforcement Discretion

Despite the legal prohibition, FDA has exercised enforcement discretion, focusing resources on products making explicit disease claims, products marketed to children, or products containing contaminants or inaccurate labeling. A 2020 FDA study found that 18 of 30 tested CBD products contained less than 80% of the labeled CBD content, and several contained significant THC levels. The agency has not systematically removed CBD products from the market, creating a de facto tolerance for products marketed with general wellness claims rather than therapeutic claims.

FTC Advertising Regulation

The Federal Trade Commission has pursued deceptive advertising cases against CBD companies under Section 5 of the FTC Act (15 U.S.C. § 45). In 2020, FTC issued warning letters to six companies for making unsubstantiated claims that CBD products could treat or cure diseases including cancer, Alzheimer's disease, and opioid addiction. For sleep claims specifically, FTC requires competent and reliable scientific evidence, typically interpreted as at least one adequate and well-controlled human clinical trial, before companies can make efficacy claims.

State Hemp and CBD Laws

States have implemented varying regulatory approaches to hemp-derived CBD. California requires CBD products to comply with both hemp regulations under the Department of Food and Agriculture and cannabis regulations under the Department of Cannabis Control, creating overlapping jurisdiction. New York's Department of Agriculture and Markets issued regulations in 2023 requiring CBD products to be registered, tested for potency and contaminants, and labeled with specific warnings. Ohio permits hemp-derived CBD sales but prohibits therapeutic claims beyond those allowed by FDA.

Pharmaceutical Approval Pathways

CBD products seeking approval as drugs must complete the FDA new drug application process under 21 C.F.R. § 314, including preclinical studies, Phase I safety trials, Phase II dose-finding trials, and Phase III efficacy trials. The Epidiolex approval established precedent for CBD drug development, including acceptable safety profiles at doses up to 20 mg/kg/day and required monitoring for liver enzyme elevations. For insomnia indications, FDA typically requires trials demonstrating improvement in sleep latency, total sleep time, or wake after sleep onset measured by polysomnography, with trial durations of at least 3-6 months to assess long-term safety and efficacy.

State-by-State Breakdown

Hemp-derived CBD is legal for sale in all 50 states following the 2018 Farm Bill, but states have implemented varying testing, registration, and labeling requirements that create compliance complexity for interstate commerce.

California

California permits hemp-derived CBD sales under the Department of Food and Agriculture's hemp program, requiring products to contain less than 0.3% THC and be tested by ISO-accredited laboratories. However, CBD cannot be added to conventional foods pending FDA action, creating ambiguity for edible products. The Department of Cannabis Control regulates cannabis-derived CBD separately, requiring products to be sold only through licensed dispensaries. Sleep claims on hemp CBD products must comply with FDA and FTC standards, with the state Attorney General pursuing enforcement actions against companies making unsubstantiated therapeutic claims. California's Proposition 65 requires warning labels on products containing chemicals known to cause cancer or reproductive harm, though CBD itself is not listed.

New York

New York's Department of Agriculture and Markets issued comprehensive CBD regulations in 2023 requiring all hemp-derived CBD products to be registered with the state, tested for cannabinoid content and contaminants including heavy metals and pesticides, and labeled with specific information including CBD content per serving, batch number, and manufacturer contact information. Products must contain less than 0.3% THC and cannot make disease treatment claims. The state's Office of Cannabis Management regulates cannabis-derived CBD separately. New York has been active in enforcement, with the Department of Agriculture conducting market surveillance and removing non-compliant products.

Texas

Texas legalized hemp cultivation and CBD production in 2019 through House Bill 1325, aligning state law with the 2018 Farm Bill. The Texas Department of State Health Services initially proposed regulations that would have restricted CBD to licensed dispensaries, but revised its position in 2020 to allow general retail sales of hemp-derived CBD. Products must contain less than 0.3% THC and comply with federal food and drug laws. Texas has not implemented state-specific testing or registration requirements beyond federal standards, but the Attorney General's office has pursued consumer protection cases against companies making false therapeutic claims.

Florida

Florida permits hemp-derived CBD sales under the Department of Agriculture and Consumer Services' hemp program established in 2019. Products must contain less than 0.3% THC and be tested by approved laboratories. Florida does not require state registration of CBD products but enforces compliance with federal food and drug laws. The state's medical cannabis program, regulated by the Department of Health, operates separately and requires physician certification for cannabis-derived CBD products. Florida has seen significant CBD market growth, with retail sales estimated at $340 million in 2025 according to Hemp Industry Daily.

Ohio

Ohio legalized hemp and hemp-derived CBD in 2019 through Senate Bill 57, establishing a regulatory program under the Department of Agriculture. Products must contain less than 0.3% THC and be tested for potency and contaminants. Ohio requires hemp processors to be licensed by the state and maintain records of all products manufactured. The state prohibits therapeutic claims on CBD products beyond those permitted by FDA, and the Board of Pharmacy has clarified that CBD products cannot be marketed as dietary supplements pending federal regulatory action. Ohio's medical marijuana program, regulated separately, allows cannabis-derived CBD for registered patients.

Colorado

Colorado, an early adopter of both medical and recreational cannabis, regulates hemp-derived CBD through the Department of Agriculture under rules established in 2019. Products must contain less than 0.3% THC and be tested by registered laboratories. Colorado does not require state registration of individual CBD products but licenses hemp cultivators and processors. The state's Marijuana Enforcement Division regulates cannabis-derived CBD separately, requiring products to be sold through licensed dispensaries. Colorado has been relatively permissive in allowing CBD sales while enforcing testing and labeling accuracy.

Market and Business Implications

Pharmaceutical validation of CBD for insomnia could bifurcate the market into prescription medications with regulatory approval and over-the-counter wellness products facing increased scrutiny, with implications for pricing, reimbursement, and competitive positioning.

Pharmaceutical Market Opportunity

The prescription insomnia medication market in the United States reached $2.1 billion in 2025, dominated by drugs including Belsomra (suvorexant), Ambien (zolpidem), and Lunesta (eszopiclone). A prescription CBD insomnia medication would enter a market where many existing drugs face generic competition and payer pressure on pricing. However, a novel mechanism of action and potentially favorable side effect profile compared to benzodiazepines could support premium pricing. Analysts at Cantor Fitzgerald estimated that a CBD insomnia drug could achieve peak annual sales of $400-600 million in Australia alone if approved, with potential for global expansion to markets including Canada, the United Kingdom, and European Union countries.

Insurance Reimbursement Dynamics

Prescription drug coverage for insomnia medications varies by payer, with many insurance plans requiring prior authorization or step therapy demonstrating failure of behavioral interventions before covering pharmacotherapy. A CBD insomnia medication would need to demonstrate cost-effectiveness compared to existing treatments to secure favorable formulary placement. The wholesale acquisition cost for Epidiolex of approximately $32,500 annually has limited uptake despite FDA approval, with many insurers requiring extensive documentation of medical necessity. An insomnia-indicated CBD product would likely be priced lower to compete with generic hypnotics, potentially in the range of $200-400 per month based on industry pricing models.

Hemp-Derived CBD Market Impact

The consumer CBD market reached $4.9 billion in U.S. sales in 2025, with sleep products representing approximately 25% of sales according to the Brightfield Group. Pharmaceutical approval of CBD for insomnia could have contradictory effects on this market. Positive clinical trial results might validate consumer interest and drive increased sales of over-the-counter CBD sleep products. However, increased FDA scrutiny and enforcement actions against companies making therapeutic claims could constrain marketing and reduce consumer confidence in unregulated products.

The pricing differential between pharmaceutical CBD and hemp-derived CBD is substantial. Consumer CBD sleep products typically cost $30-80 per month for daily use, compared to potential prescription costs of $200-400 monthly. This price gap could sustain a two-tier market where consumers seeking lower-cost options continue purchasing hemp-derived products despite lack of FDA approval, while patients with insurance coverage or severe insomnia access prescription formulations.

Multi-State Operator Considerations

Cannabis multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have largely focused on THC products rather than CBD due to higher margins and consumer demand. However, pharmaceutical validation of CBD could prompt MSOs to invest in pharmaceutical-grade CBD production and clinical development. The challenge for MSOs is that cannabis-derived CBD remains federally illegal outside the drug approval process, while hemp-derived CBD faces FDA restrictions on therapeutic claims. Some MSOs have established separate hemp divisions to access the legal CBD market, but have found it difficult to compete with lower-cost hemp producers on commodity CBD products.

Investment and Capital Flows

Venture capital and private equity investment in CBD companies declined from a peak of $1.2 billion in 2019 to $340 million in 2025, according to Viridian Capital Advisors, reflecting market saturation and regulatory uncertainty. Pharmaceutical CBD development has attracted different capital sources, including traditional pharmaceutical investors and public market funding. Avecho Biotechnology raised AUD $15 million through a share placement in 2024 to fund its Phase III trial, with institutional investors including Australian superannuation funds participating. Successful regulatory approval could catalyze increased investment in pharmaceutical cannabinoid development, while continued FDA inaction on dietary supplement pathways may further constrain consumer CBD investment.

International Market Expansion

Regulatory approval in Australia could facilitate market entry in other jurisdictions through regulatory reliance mechanisms. The United Kingdom's Medicines and Healthcare products Regulatory Agency, Health Canada, and the European Medicines Agency often consider approval decisions from reference regulatory authorities including the TGA when evaluating new drug applications. This could enable faster approval timelines in multiple markets compared to conducting separate trials in each jurisdiction. However, each regulator maintains independent authority and may require additional data or impose different labeling requirements.

What Experts Say

Sleep medicine specialists, pharmacologists, and regulatory experts have expressed cautious interest in CBD insomnia research while emphasizing the need for rigorous clinical evidence and clear regulatory frameworks.

Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, has stated in published interviews that while preclinical evidence suggests CBD may influence sleep-related neurotransmitter systems, human clinical trials have produced inconsistent results, with some studies showing no benefit and others showing modest improvements. He emphasized that factors including dose, timing, formulation, and individual patient characteristics likely influence outcomes, making it difficult to draw broad conclusions from existing research.

Dr. Danielle Friedman, a neurologist at New York University Langone Health who served as principal investigator for Epidiolex epilepsy trials, noted in a 2025 medical conference presentation that CBD's safety profile in the Epidiolex trials was generally favorable, with the most common adverse effects being elevated liver enzymes, diarrhea, and fatigue. She indicated that these findings provide a foundation for investigating CBD in other indications, though each therapeutic application requires specific clinical trials to establish efficacy and safety in the target population.

According to Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at the University of California San Diego, speaking at a 2024 symposium, the challenge with CBD research is that the compound has multiple pharmacological targets and its effects may depend on the specific condition being treated. He suggested that CBD might be more effective for sleep disturbances secondary to other conditions such as anxiety or chronic pain rather than primary insomnia, and that future research should focus on identifying patient subgroups most likely to benefit.

Dr. Ryan Vandrey, professor of psychiatry and behavioral sciences at Johns Hopkins University School of Medicine, has published research examining CBD's effects in various populations. In a 2025 interview with JAMA, he noted that many consumer CBD products contain inaccurate labeling and variable CBD content, making it difficult for consumers to dose consistently or for researchers to interpret real-world use patterns. He emphasized the need for pharmaceutical-grade formulations with consistent bioavailability to enable meaningful clinical research.

From a regulatory perspective, Dr. Douglas Throckmorton, former deputy director of the FDA Center for Drug Evaluation and Research, stated in congressional testimony in 2023 that FDA's concerns about CBD in dietary supplements include potential drug interactions, effects on liver function, and lack of long-term safety data in healthy populations. He indicated that while the agency recognizes public interest in CBD products, the drug approval pathway provides the most rigorous framework for establishing safety and efficacy.

Industry perspectives have emphasized the commercial potential while acknowledging regulatory challenges. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has argued in public statements that FDA's current policy creates a regulatory vacuum that harms both consumers and legitimate businesses, and that the agency should establish clear pathways for CBD dietary supplements with appropriate safety guardrails rather than maintaining a prohibition that is not meaningfully enforced.

What's Next

The regulatory trajectory for CBD insomnia products will be determined by pending FDA policy decisions, completion of ongoing clinical trials, and potential legislative action to establish clear pathways for non-pharmaceutical CBD products.

Immediate Regulatory Milestones

Avecho Biotechnology has announced plans to submit a New Drug Application to the Australian Therapeutic Goods Administration in the fourth quarter of 2026, with a decision expected within 12-18 months following submission. If approved, the product could launch in the Australian market in 2027 or 2028, establishing the first regulatory precedent for a CBD insomnia medication. The company has indicated interest in pursuing regulatory approval in additional markets including Canada and the United Kingdom, though timelines for those submissions have not been announced.

In the United States, FDA has not provided a timeline for issuing proposed regulations on CBD in dietary supplements or foods, despite stating since 2019 that the agency is working on a regulatory framework. Congressional pressure has increased, with multiple bills introduced in 2025 and 2026 that would direct FDA to establish clear pathways within specified timeframes. The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, if passed, would require FDA to issue regulations within 180 days, though the legislation had not advanced out of committee as of July 2026.

Ongoing Clinical Research

Several additional CBD insomnia trials are in progress or planned. A Phase II trial at the University of Colorado is examining CBD combined with behavioral therapy for insomnia in military veterans, with results expected in late 2026. A trial at the University of Pennsylvania is investigating CBD's effects on sleep in individuals with post-traumatic stress disorder, with completion anticipated in 2027. These studies will add to the evidence base and may identify specific patient populations where CBD shows particular promise.

Researchers have also begun investigating combination formulations of CBD with other cannabinoids or sleep-promoting compounds. A trial in Canada is examining a 20:1 CBD:THC ratio product for insomnia, based on the hypothesis that small amounts of THC may enhance CBD's sleep-promoting effects while minimizing intoxication. Another study is investigating CBD combined with melatonin, a hormone that regulates circadian rhythms and is widely used as an over-the-counter sleep aid.

Market Evolution Scenarios

The CBD insomnia market could evolve along several potential trajectories depending on regulatory developments. In a pharmaceutical-dominated scenario, companies would pursue drug approval for specific CBD formulations, creating a market of prescription products with demonstrated efficacy but higher costs and access barriers. This pathway would likely result in consolidation, with larger pharmaceutical companies acquiring smaller CBD developers or licensing their technologies.

In a dietary supplement pathway scenario, FDA would establish regulations allowing CBD in supplements with appropriate safety testing and labeling requirements but without requiring clinical efficacy trials. This would legitimize the existing consumer market while implementing quality standards, potentially expanding the market by increasing consumer confidence. However, products could not make disease treatment claims and would be marketed for general wellness support.

In a continued status quo scenario, FDA would maintain its current position that CBD cannot be marketed in dietary supplements, while exercising enforcement discretion that allows products to remain on the market if they avoid explicit therapeutic claims. This would perpetuate regulatory uncertainty and market fragmentation, with consumers accessing products